Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates through two segments, Services and True Health. The Services segment provides value-based care services that include Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows and engages patients; population health performance that delivers patient-centric cost effective care; and delivery network alignments. This segment also offers specialty care management solutions that support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation, and specific market dynamics; and comprehensive health plan administrative services that helps providers assemble the complete infrastructure required to operate, manage, and capitalize on a variety of financial and administrative management services. The True Health segment operates a commercial health plan for small and large businesses in New Mexico. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
IPO Year: 2015
Exchange: NYSE
Website: evolenthealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $15.00 | Buy | Needham |
| 12/3/2024 | $36.00 → $29.00 | Buy | BTIG Research |
| 11/8/2024 | $38.00 → $16.00 | Overweight → Equal-Weight | Stephens |
| 10/11/2024 | $35.00 | Overweight | KeyBanc Capital Markets |
| 8/9/2024 | $28.00 → $33.00 | Hold → Buy | Truist |
| 4/22/2024 | $40.00 | Buy | Citigroup |
| 3/1/2024 | $45.00 | Outperform | Oppenheimer |
| 1/3/2024 | $39.00 | Overweight | Barclays |
| 12/6/2023 | $37.00 | Mkt Outperform | JMP Securities |
| 10/16/2023 | $46.00 | Buy | UBS |
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
Former CFO of CVS Health, Aetna and Coventry Health Care brings deep experience driving growth and profitability.Mr. Guertin's nomination represents continuation of Evolent's board refreshment efforts.WASHINGTON, April 22, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced that a new director nominee will stand for election to the Board of Directors at the annual meeting of stockholders scheduled to be held on June 5, 2025. The Board has recommended Mr. Shawn Guertin for election. Mr. Guertin is an insurance and health care executive with nearly 40 years of actuarial, fina
Program aims to achieve the best possible treatment outcomes — longer lives with fewer side-effects — without excess financial strain. Collegial provider engagement model brings together education, technology and incentives to encourage top-quality regimens. One low-value regimen costs about 70 times more than a clinically equivalent alternative.WASHINGTON, April 15, 2025 /PRNewswire/ -- When treating patients with cancer, oncologists typically can choose from multiple FDA-approved regimens, or combinations of drugs. While tools such as Evolent's clinical pathways can help them find high-value options, providers have not had similar resources to flag regimens on the opposite side of the spec
Company to Participate in Upcoming Conferences WASHINGTON, April 10, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolen
Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go
The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.
Believes Incumbent Board's Approval and Ongoing Pursuit of Reckless and Dilutive Proposed Merger with Akoya Biosciences Demonstrates Urgent Need for Refreshment Nominees Would Bring Deep Healthcare and Financial Experience Necessary to Properly Oversee a Standalone Quanterix, Prevent Further Capital Misallocation and Improve Shareholder Value Kent Lake Urges Shareholders to Vote Against Merger with Akoya to Protect the Future Value of Their Investment Kent Lake PR LLC ("Kent Lake"), a holder of 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), announced today it has nominated three highly qualified, independent candidates for e
Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, representing 16.3% and 30.1% growth over 2023, respectively.Net loss attributable to common shareholders of Evolent Health, Inc. of $30.6 million for three months ended December 31, 2024 and $93.5 million for the year ended December 31, 2024, resulting in a net loss margin of (4.7)% and (3.7)%, respectively.Adjusted EBITDA of $22.6 million for the three months ended December 31, 2024 and $160.5 million for the year ended December 31, 2024, resulting in an Adjusted EBITDA margin of 3.5% and 6.3%, respectively.Signed contract amendments in all three Performance Suit
Richard "Rick" Jelinek to Be Named Chair of the Board at 2025 Annual Meeting Company Continues Board Refreshment Efforts with Brendan Springstubb's Appointment as New Independent Director WASHINGTON, Feb. 4, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced changes to its Board of Directors as part of the Company's ongoing commitment to strong corporate governance and to collaboration with shareholders. Rick Jelinek, who joined the Evolent Board as an independent director in 2023, will be named Chair of the Board at the 2025 Annual Meeting, succeeding Cheryl Scott. Mr. J
Company to Participate in Upcoming Conferences WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its fourth quarter 2024 financial results on Thursday, February 20, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "
Longtime CMO Dr. Andrew Hertler to serve as senior advisor and CMO emeritus. WASHINGTON, Dec. 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025. Dr. Nguyen joined Evolent as Chief Clinical Officer in July 2024 after serving as clinical lead for population health at Google. Among other previous roles, he has been Chief Medical Officer at Blue Cross North Carolina, Deputy Associate Director of Policy and Strategy at the Centers for Disease Control and Prevention, and Senior Advisor at the Centers for Me
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SC 13G/A - Evolent Health, Inc. (0001628908) (Subject)
Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go
The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.
Longtime CMO Dr. Andrew Hertler to serve as senior advisor and CMO emeritus. WASHINGTON, Dec. 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025. Dr. Nguyen joined Evolent as Chief Clinical Officer in July 2024 after serving as clinical lead for population health at Google. Among other previous roles, he has been Chief Medical Officer at Blue Cross North Carolina, Deputy Associate Director of Policy and Strategy at the Centers for Disease Control and Prevention, and Senior Advisor at the Centers for Me
The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie
WASHINGTON, Dec. 1, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Seth R. Frank has joined the company as Vice President, Investor Relations, effective immediately. Reporting to John Johnson, Evolent's Chief Financial Officer, Seth will lead Evolent's investor relations (IR) strategy and oversee its relationships with the investment community. "Seth provides a demonstrated track record of proactive, finance-driven leadership in health care investor relations to Evolent," said Evolent Health Chief Financial Officer John Johnson. "He brings long-ter
WASHINGTON, Jan. 13, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Kim A. Keck has been appointed to its Board of Directors, effective immediately and will stand for election at the Company's 2021 annual meeting of stockholders. Ms. Keck has more than 30 years' experience in the health care industry and currently serves as President and Chief Executive Officer of the Blue Cross Blue Shield Association (BCBSA), a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield companies that provide health care coverag
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
4 - Evolent Health, Inc. (0001628908) (Issuer)
DEFA14A - Evolent Health, Inc. (0001628908) (Filer)
DEF 14A - Evolent Health, Inc. (0001628908) (Filer)
8-K - Evolent Health, Inc. (0001628908) (Filer)
144 - Evolent Health, Inc. (0001628908) (Subject)
8-K - Evolent Health, Inc. (0001628908) (Filer)
SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)
SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)
8-K - Evolent Health, Inc. (0001628908) (Filer)
8-K - Evolent Health, Inc. (0001628908) (Filer)
8-K - Evolent Health, Inc. (0001628908) (Filer)
Needham initiated coverage of Evolent Health with a rating of Buy and set a new price target of $15.00
BTIG Research reiterated coverage of Evolent Health with a rating of Buy and set a new price target of $29.00 from $36.00 previously
Stephens downgraded Evolent Health from Overweight to Equal-Weight and set a new price target of $16.00 from $38.00 previously
KeyBanc Capital Markets initiated coverage of Evolent Health with a rating of Overweight and set a new price target of $35.00
Truist upgraded Evolent Health from Hold to Buy and set a new price target of $33.00 from $28.00 previously
Citigroup initiated coverage of Evolent Health with a rating of Buy and set a new price target of $40.00
Oppenheimer initiated coverage of Evolent Health with a rating of Outperform and set a new price target of $45.00
Barclays initiated coverage of Evolent Health with a rating of Overweight and set a new price target of $39.00
JMP Securities initiated coverage of Evolent Health with a rating of Mkt Outperform and set a new price target of $37.00
UBS initiated coverage of Evolent Health with a rating of Buy and set a new price target of $46.00
Company to Participate in Upcoming Conferences WASHINGTON, April 10, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evolen
Revenue of $646.5 million for the three months ended December 31, 2024 and $2,554.7 million for the year ended December 31, 2024, representing 16.3% and 30.1% growth over 2023, respectively.Net loss attributable to common shareholders of Evolent Health, Inc. of $30.6 million for three months ended December 31, 2024 and $93.5 million for the year ended December 31, 2024, resulting in a net loss margin of (4.7)% and (3.7)%, respectively.Adjusted EBITDA of $22.6 million for the three months ended December 31, 2024 and $160.5 million for the year ended December 31, 2024, resulting in an Adjusted EBITDA margin of 3.5% and 6.3%, respectively.Signed contract amendments in all three Performance Suit
Company to Participate in Upcoming Conferences WASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its fourth quarter 2024 financial results on Thursday, February 20, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "
Revenue of $621.4 million, an increase of $110.4 million or 21.6%, from the three months ended September 30, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(31.2) million and a net loss margin of (5.0)%.Adjusted EBITDA of $31.8 million resulting in an Adjusted EBITDA margin of 5.1%.Revises outlook for Adjusted EBITDA for 2024.Reiterates average annual long-term revenue and average Adjusted EBITDA growth rate targets.Announces record six new contract agreements in the quarter.WASHINGTON, Nov. 7, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions th
Company to Participate in Upcoming Conferences WASHINGTON, Oct. 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its third quarter 2024 financial results on Thursday, November 7, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9
Revenue of $647.1 million, an increase of $178.0 million or 37.9%, from the three months ended June 30, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(6.4) million and a net loss margin of (1.0)%.Adjusted EBITDA of $52.0 million resulting in an Adjusted EBITDA margin of 8.0%.Narrows revenue outlook for full year 2024 and provides updated 2024 Adjusted EBITDA guidance.Reiterates confidence in achieving $300 million in Adjusted EBITDA run rate exiting 2024.WASHINGTON, Aug. 8, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care
Company to Participate in Upcoming Conferences WASHINGTON, July 11, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced it will release its second quarter 2024 financial results on Thursday, August 8, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations
Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023.Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%.Adjusted EBITDA of $54.1 million resulting in an Adjusted EBITDA margin of 8.5%.Raises revenue outlook for full year 2024 and reiterates full year 2024 Adjusted EBITDA guidance.WASHINGTON, May 9, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the quarter ended
Company to Participate in Upcoming Conferences WASHINGTON, April 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable, today announced it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference found on Evolent's investor relations website, https://ir.evolenthealth.com. Analysts interested in asking questions during the live call should dial 855.940.
WASHINGTON, Feb. 22, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months and year ended December 31, 2023. Seth Blackley, Chief Executive Officer, and Co-Founder of Evolent stated, "We ended 2023 on a strong note, achieving all of our financial objectives for the year. Annual revenue increased over 45% while we continued to deliver strong earnings, driven by continued underlying growth as well as the successful integration of NIA. I am incredibly proud of our global team who